Pelthos Therapeutics EBIT

Pelthos Therapeutics (PTHS) currently reports a EBIT of $-30M as of June 2026. That compares with $-11M in the prior-year period — down 187.2% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Pelthos Therapeutics's EBIT history and peer comparisons.

Pelthos Therapeutics's EBIT decreased from $-11M to $-30M — a 187.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pelthos Therapeutics's EBIT of $-30M is lower than the its sector sector average of $-6.4M. That is roughly 371.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Pelthos Therapeutics reported $-30M in EBIT as of June 2026. That compares with $-11M in the prior-year period — down 187.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Pelthos Therapeutics, and consider following PTHS for alerts when major investors trade the stock.